Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab Data highlighted in late-breaking presentation at…
Multi-year investment of USD 300m will create integrated scientific environment to deliver on increasing growth and diversity of biotherapeutics portfolio Enhanced capacity and processes expected…
PfizerInc.( NYSEPFE) moment blazoned that its investigational Group B Streptococcus( GBS) vaccine seeker, GBS6 or PF- 06760805, entered Advance remedy Designation from theU.S. Food and…
Allergan Aesthetics, an AbbVie company( NYSE ABBV), blazoned its manufacturing installation in France has reached the corner of producing and dispatching 100 million hypesof JUVÉDERM…
Results from the study showed a dults and children aged 13 and older with uncontrolled asthma using the ProAir Digihaler and its integrated system had 85.3%…
Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by…
Approval Marks Kite’s Fourth Indication in Europe for its Two Cell Therapies and First in Leukemia — — Overall Complete Remission of 71% and a Median…
The OCTARAY ™ Mapping Catheter with TRUEref ™ Technology provides croakerswith the precise information demanded for catheter ablation procedures that treat cardiac arrhythmias( 1),( 2),(…
First prequalification for a malaria vaccineImportant step for rolling out the vaccine to children living in regions with moderate to high transmissionGSK plc( LSE/ NYSE…
Approval marks the first SGLT2 inhibitor approved in China for chronic kidneydisease in adult patients with and without type-2 diabetes AstraZeneca’s Forxiga( dapagliflozin), a sodium-…
InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at the European Respiratory Society…
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine The Omicron BA.1-adapted bivalent COVID-19 vaccine…